Your browser doesn't support javascript.
loading
Model-Informed Dose Selection for Xentuzumab, a Dual Insulin-Like Growth Factor-I/II-Neutralizing Antibody.
Parra-Guillen, Zinnia P; Schmid, Ulrike; Janda, Alvaro; Freiwald, Matthias; Troconiz, Iñaki F.
Afiliação
  • Parra-Guillen ZP; Pharmacometrics & Systems Pharmacology Research Unit, Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain.
  • Schmid U; Navarra Institute for Health Research, IdiSNA, Pamplona, Spain.
  • Janda A; Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riß, Germany.
  • Freiwald M; Pharmacometrics & Systems Pharmacology Research Unit, Department of Pharmaceutical Technology and Chemistry, School of Pharmacy and Nutrition, University of Navarra, Pamplona, Spain.
  • Troconiz IF; Navarra Institute for Health Research, IdiSNA, Pamplona, Spain.
Clin Pharmacol Ther ; 107(3): 597-606, 2020 03.
Article em En | MEDLINE | ID: mdl-31562819
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fator de Crescimento Insulin-Like I / Fator de Crescimento Insulin-Like II / Anticorpos Monoclonais Humanizados / Modelos Biológicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fator de Crescimento Insulin-Like I / Fator de Crescimento Insulin-Like II / Anticorpos Monoclonais Humanizados / Modelos Biológicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article